Search

Search results

817 results found

Adjunctive therapy with an oral H2S donor provides additional therapeutic benefit beyond SGLT2 inhibition in cardiometabolic heart failure with preserved ejection fraction.

Doiron, Jake E, Huijing Xia, Xiaoman Yu, Alexandra R Nevins, Kyle B LaPenna, Thomas E Sharp, Traci T Goodchild, et al. 2024. “Adjunctive Therapy With an Oral H2S Donor Provides Additional Therapeutic Benefit Beyond SGLT2 Inhibition in Cardiometabolic Heart Failure With Preserved Ejection Fraction.”. British Journal of Pharmacology 181 (21): 4294-4310.